A Small-scale Phase IV Clinical Trial of Two Non-ergot Dopamine Agonists: Slowly Switching from Ropinirole to Pramipexole in Patients with Parkinson''s Disease
碩士 === 臺北醫學大學 === 藥學研究所 === 97 === Background: Dopamine receptor agonists (DAs), especially D2 subtype could be used as monotherapy in patients with early Parkinson’s disease (PD) or adjunctive therapy to L-DOPA in advanced PD with motor complications. DAs are divided into ergot and non-ergot agent...
Main Authors: | Shin-Chia Tsai, 蔡欣佳 |
---|---|
Other Authors: | 劉景平 |
Format: | Others |
Language: | en_US |
Published: |
2009
|
Online Access: | http://ndltd.ncl.edu.tw/handle/59967084075455423785 |
Similar Items
-
Parkinson's disease fatigability and its correction with the dopamine receptor agonist pramipexole
by: M. R. Nodel
Published: (2011-12-01) -
Capacities of the dopamine receptor agonist pramipexole in the treatment of patients with Parkinson’s disease
by: S N Illarioshkin
Published: (2012-06-01) -
Feasibility of a randomized single-blind crossover trial to assess the effects of the second-generation slow-release dopamine agonists pramipexole and ropinirole on cued recall memory in idiopathic mild or moderate Parkinson’s disease without cognitive impairment
by: Thomas A. Shepherd, et al.
Published: (2017-07-01) -
Ophthalmologic Baseline Characteristics and 2-Year Ophthalmologic Safety Profile of Pramipexole IR Compared with Ropinirole IR in Patients with Early Parkinson’s Disease
by: William Seiple, et al.
Published: (2016-01-01) -
The effect of dopamine and its agonist pramipexole on oligodendrocytes in culture and in the cuprizone mouse model
by: Richter, Johann Sebastian
Published: (2014)